A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Inclusion Criteria

• •1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.
• •2. Age ≥ 18 years at the time of signing the informed consent.
• •3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
• •4. The expected survival time is at least 12 weeks.
• •5. According to the evaluation of RECIST 1.1 standard, the subjects enrolled have at least one measurable lesion.
• •6. There is adequate organ and bone marrow function,Conforms to laboratory test results.
• •7. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.